Changeflow GovPing Healthcare & Life Sciences IL-2 Compositions by Proviva Therapeutics, publ...
Routine Rule Added Final

IL-2 Compositions by Proviva Therapeutics, published Apr 15

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3976638A1 titled "IL-2 Compositions and Methods of Use Thereof" for Proviva Therapeutics (Hong Kong) Limited. The invention covers IL-2 (interleukin-2) compositions for therapeutic use, with inventor Zijuan Li listed. The patent is classified under IPC categories C07K 14/55, C07K 14/715, C07K 16/24, A61K 47/64, and A61K 47/68. Designated states cover all 31 EEA countries plus the UK and Switzerland.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.

What changed

The EPO published patent application EP3976638A1 for IL-2 compositions and their therapeutic methods, filed by Proviva Therapeutics (Hong Kong) Limited. The invention relates to interleukin-2 (IL-2) compositions classified across multiple IPC subclasses including C07K peptide classifications and A61K pharmaceutical formulations. Designated states include all 31 European Patent Convention contracting states plus Switzerland and the United Kingdom.

For biopharmaceutical companies and researchers in the IL-2/immunotherapy space, this patent establishes IP protection for Proviva's compositions. Competitors developing similar IL-2 formulations should conduct freedom-to-operate analyses. Investors tracking Proviva Therapeutics should note this strategic IP filing in the immunotherapy domain.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

IL-2 COMPOSITIONS AND METHODS OF USE THEREOF

Publication EP3976638A1 Kind: A1 Apr 15, 2026

Applicants

Proviva Therapeutics (Hong Kong) Limited

Inventors

LI, Zijuan

IPC Classifications

C07K 14/55 20060101AFI20230719BHEP C07K 14/715 20060101ALI20230719BHEP C07K 16/24 20060101ALI20230719BHEP A61K 47/64 20170101ALI20230719BHEP A61K 47/68 20170101ALI20230719BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3976638A1

Who this affects

Applies to
Pharmaceutical companies Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting Biopharmaceutical research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!